On 07 November 2025, Alphamab Oncology (stock code 09966) disclosed a repurchase of 560,000 ordinary shares on The Stock Exchange of Hong Kong. Following this transaction, the company's total issued shares excluding treasury shares changed from 970,074,697 to 969,514,697, while its treasury share holdings increased from 4,073,000 to 4,633,000.

The closing balance of issued shares stood at 974,147,697, comprising 969,514,697 issued shares (excluding treasury shares) and 4,633,000 treasury shares. According to the filing, the highest repurchase price was HKD 9.52 per share and the lowest was HKD 9.24 per share, with an aggregate consideration of HKD 5,260,970. The repurchase was carried out under a mandate dated 12 June 2025 that authorized the company to repurchase up to 96,218,980 shares. Since that resolution, a total of 1,681,000 shares have been repurchased, representing approximately 0.1747% of the issued ordinary shares at the time of the mandate.